Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market
Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market
MONTREAL, May 16, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: "SBFM"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today closed its previously announced private placement pursuant to a securities purchase agreement with a single healthcare-focused institutional investor for gross proceeds of approximately $5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.
蒙特利尔，2023年5月16日(环球网)--阳光生物制药公司(纳斯达克股票代码：“SBFM”)，一家在肿瘤和抗病毒药物等多种治疗领域提供和研究救命药物的制药公司，今天根据与一家专注于医疗保健的机构投资者达成的证券购买协议，完成了先前宣布的定向增发，总收益约为500万美元，然后扣除配售代理费用和该公司应支付的其他发售费用。
In connection with the private placement, the Company issued 5,952,381 units and pre-funded units at a purchase price of $0.84 per unit (or $0.001 less per pre-funded unit), priced at-the-market under Nasdaq rules. Each unit or pre-funded unit consists of one share of common stock (or pre-funded warrant) and two non-tradable warrants each exercisable for $0.59 for one share of common stock (for a total of 11,904,762 shares underlying the warrants). The warrants have a term of five and a half years from the issuance date. No actual units were issued.
在定向增发方面，本公司发行了5,952,381个单位和预融资单位，收购价为每单位0.84美元(或每个预融资单位减少0.001美元)，按纳斯达克规则按市场定价。每个单位或预筹资金单位包括一股普通股(或预筹资权证)和两份非流通权证，每份认股权证可按0.59美元换取一股普通股(总计11,904,762股认股权证)。认股权证的有效期为自发行之日起计五年半。没有发放任何实际的单位。
Aegis Capital Corp. acted as the Exclusive Placement Agent in connection with the offering.
Aegis Capital Corp.担任此次发行的独家配售代理。
The securities described were sold in a private placement and have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the "SEC") or an applicable exemption from such registration requirements. The securities were offered only to an accredited investor. Pursuant to a registration rights agreement with the investor, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock and the shares of common stock issuable upon exercise of the warrants and pre-funded warrants.
上述证券是以私募方式出售的，并未根据1933年修订的《证券法》进行登记，未经美国证券交易委员会(以下简称“美国证券交易委员会”)登记或获得此类登记要求的豁免，不得在美国发售或出售。这些证券只提供给经过认可的投资者。根据与投资者订立的登记权协议，本公司已同意向美国证券交易委员会提交一份或多份登记声明，内容包括回售普通股股份及行使认股权证及预筹资权证后可发行的普通股股份。
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
本新闻稿不应构成出售或邀请购买本文所述任何证券的要约，也不应在任何州或司法管辖区出售这些证券，在这些州或司法管辖区的任何州或司法管辖区，在根据任何州或司法管辖区的证券法进行登记或获得资格之前，此类要约、招揽或出售将是非法的。
About Sunshine Biopharma
关于阳光生物医药
Sunshine Biopharma recently acquired Nora Pharma Inc. and as a result the Company now has 50 generic prescription drugs on the market in Canada and 48 employees. The Company is planning to expand its product offering to 86 generic pharmaceuticals over the next two years. In parallel, Sunshine Biopharma is continuing its proprietary drug development program which is comprised of (i) K1.1 mRNA for liver cancer, (ii) Adva-27a, a small chemotherapy molecule for pancreatic cancer, and (iii) PLpro inhibitor for COVID-19. For more information, please visit:
阳光生物制药公司最近收购了Nora Pharma Inc.，因此，该公司目前在加拿大市场上有50种非专利处方药和48名员工。该公司计划在未来两年内将其产品供应扩大到86种仿制药。与此同时，阳光生物仍在继续其专利药物开发计划，该计划包括(I)治疗肝癌的K1.1mRNA，(Ii)治疗胰腺癌的小化学分子Adva-27A，以及(Iii)治疗新冠肺炎的PLPro抑制剂。如需更多信息，请访问：
Cautionary Note Regarding Forward Looking Statements
有关前瞻性陈述的注意事项
This press release contains "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as "may", "could", "expects", "projects," "intends", "plans", "believes", "predicts", "anticipates", "hopes", "estimates" and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the Company's control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in the Company's filings with the SEC. The Company's SEC filings can be obtained free of charge on the SEC's website at www.sec.gov. Except to the extent required by law, the Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
本新闻稿包含有关未来事件的“前瞻性陈述”(定义见修订后的1933年证券法第27A节和修订后的1934年证券交易法第21E节)。诸如“可能”、“可能”、“预期”、“项目”、“打算”、“计划”、“相信”、“预测”、“预期”、“希望”、“估计”等词语以及此类词语和类似表述的变体旨在识别前瞻性陈述。这些陈述涉及已知和未知的风险，并基于一些假设和估计，这些假设和估计本身就会受到重大不确定性和意外情况的影响，其中许多不是公司所能控制的。实际结果可能与这些前瞻性陈述中明示或暗示的结果大不相同。可能导致实际结果大不相同的因素包括但不限于该公司提交给美国证券交易委员会的文件中描述的风险因素。公司的美国证券交易委员会备案文件可以在美国证券交易委员会的网站上免费获得，网址为www.sec.gov。除法律要求的范围外，公司明确表示不承担任何义务或承诺公开发布对本文中包含的任何前瞻性陈述的任何更新或修订，以反映公司对此的预期的任何变化，或任何陈述所基于的事件、条件或情况的任何变化。
For Additional Information:
有关其他信息，请访问：
Sunshine Biopharma Contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
阳光Biophma联系方式：
首席财务官卡米尔·塞巴利
直拨电话：514-814-0464
邮箱：camille.sebaaly@sunshinebiopharma.com